JP2023537600A5 - - Google Patents
Info
- Publication number
- JP2023537600A5 JP2023537600A5 JP2023510340A JP2023510340A JP2023537600A5 JP 2023537600 A5 JP2023537600 A5 JP 2023537600A5 JP 2023510340 A JP2023510340 A JP 2023510340A JP 2023510340 A JP2023510340 A JP 2023510340A JP 2023537600 A5 JP2023537600 A5 JP 2023537600A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic agent
- rspa
- targeted therapeutic
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064555P | 2020-08-12 | 2020-08-12 | |
| US63/064,555 | 2020-08-12 | ||
| US202163168120P | 2021-03-30 | 2021-03-30 | |
| US63/168,120 | 2021-03-30 | ||
| PCT/US2021/045556 WO2022035970A1 (en) | 2020-08-12 | 2021-08-11 | Replication stress pathway agent compositions and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537600A JP2023537600A (ja) | 2023-09-04 |
| JP2023537600A5 true JP2023537600A5 (enExample) | 2024-08-20 |
Family
ID=80247345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023510340A Pending JP2023537600A (ja) | 2020-08-12 | 2021-08-11 | がんを処置するための複製ストレス経路剤組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11547711B2 (enExample) |
| EP (1) | EP4196614A4 (enExample) |
| JP (1) | JP2023537600A (enExample) |
| KR (1) | KR20230098134A (enExample) |
| CN (1) | CN116368243A (enExample) |
| AU (1) | AU2021325905A1 (enExample) |
| BR (1) | BR112023002453A2 (enExample) |
| CA (1) | CA3187760A1 (enExample) |
| MX (1) | MX2023001717A (enExample) |
| TW (1) | TW202221118A (enExample) |
| WO (1) | WO2022035970A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| EP4278185A1 (en) * | 2021-01-18 | 2023-11-22 | GBG Forschungs GmbH | Method for predicting the response to cdk4/6 inhibitor therapy in cancer patients |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CN114835640B (zh) * | 2022-05-24 | 2024-02-13 | 中国药科大学 | 成纤维细胞生长因子受体抑制剂、制备方法及应用 |
| EP4587026A1 (en) * | 2022-09-15 | 2025-07-23 | Recurium IP Holdings, LLC | Combinations |
| CN116083576B (zh) * | 2022-12-07 | 2024-01-30 | 上海市临床检验中心 | 一种基于CRISPR/Cas12a的KRAS热点基因突变检测系统和方法 |
| CN116445411A (zh) * | 2023-02-01 | 2023-07-18 | 复旦大学附属华山医院 | 一种小鼠结肠癌索托拉西布耐药细胞株及制备方法与应用 |
| EP4770642A2 (en) * | 2023-09-01 | 2026-07-08 | Boundless Bio, Inc. | Ribonucleotide reductase (rnr) compositions and methods of use |
| WO2025184572A1 (en) * | 2024-03-01 | 2025-09-04 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS567007A (en) | 1979-06-29 | 1981-01-24 | Toshiba Corp | Coating film thickness measuring apparatus |
| WO2018136837A1 (en) * | 2017-01-20 | 2018-07-26 | The Jackson Laboratory | A method of targeting patient-specific oncogenes in extrachromosomal dna to treat glioblastoma |
| MX2019012176A (es) * | 2017-04-10 | 2020-02-19 | Sierra Oncology Inc | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. |
| US11193164B2 (en) * | 2017-05-24 | 2021-12-07 | The Regents Of The University Of California | Methods of diagnosing and treating cancer targeting extrachromosomal DNA |
| AU2018278336A1 (en) * | 2017-06-01 | 2020-01-16 | Crt Pioneer Fund Lp | Biomarkers and patient selection strategies |
| US20210047693A1 (en) * | 2017-11-15 | 2021-02-18 | The Regents Of The University Of California | Methods of treating extrachromosomal dna expressing cancers |
| JP2021514979A (ja) * | 2018-02-26 | 2021-06-17 | シエラ オンコロジー， インコーポレイテッド | Ｃｈｋ１阻害剤を含む癌の治療方法 |
| WO2020123530A1 (en) * | 2018-12-10 | 2020-06-18 | The Regents Of The University Of California | Compositions and methods for modulating transcriptional activity of amplified oncogenes contained on extrachromosomal dna |
| EP3966323A4 (en) * | 2019-05-06 | 2024-04-24 | The Regents Of The University Of Michigan | Targeted therapy |
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| KR20240101555A (ko) | 2021-09-17 | 2024-07-02 | 바운드리스 바이오, 인크. | 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도 |
| EP4402134A4 (en) | 2021-09-17 | 2025-10-15 | Boundless Bio Inc | SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND THEIR USES |
| US20230272485A1 (en) | 2022-02-16 | 2023-08-31 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
-
2021
- 2021-08-11 BR BR112023002453A patent/BR112023002453A2/pt not_active Application Discontinuation
- 2021-08-11 WO PCT/US2021/045556 patent/WO2022035970A1/en not_active Ceased
- 2021-08-11 MX MX2023001717A patent/MX2023001717A/es unknown
- 2021-08-11 AU AU2021325905A patent/AU2021325905A1/en not_active Abandoned
- 2021-08-11 CN CN202180069281.4A patent/CN116368243A/zh active Pending
- 2021-08-11 JP JP2023510340A patent/JP2023537600A/ja active Pending
- 2021-08-11 EP EP21856647.9A patent/EP4196614A4/en active Pending
- 2021-08-11 KR KR1020237008613A patent/KR20230098134A/ko not_active Withdrawn
- 2021-08-11 CA CA3187760A patent/CA3187760A1/en active Pending
- 2021-08-12 TW TW110129785A patent/TW202221118A/zh unknown
-
2022
- 2022-01-04 US US17/568,434 patent/US11547711B2/en active Active
- 2022-10-21 US US18/048,573 patent/US11642345B2/en active Active
-
2023
- 2023-03-24 US US18/189,453 patent/US12246017B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aggarwal et al. | SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway–activated stage IV squamous cell lung cancer (Lung-MAP substudy) | |
| Weiss et al. | Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer | |
| JP2024526145A5 (enExample) | ||
| Sandhu et al. | Systemic treatment for metastatic colorectal cancer in the era of precision medicine | |
| Wilkes | Targeted therapy: attacking cancer with molecular and immunological targeted agents | |
| Finch et al. | P-glycoprotein and its role in drug-drug interactions | |
| US20220160714A1 (en) | Methods for treating colorectal cancer | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| Goff | Advanced ovarian cancer: what should be the standard of care? | |
| RU2020123665A (ru) | Преимущественные режимы дозирования g1т38 | |
| Minguet et al. | Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives | |
| Jing et al. | A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis | |
| KR20240074779A (ko) | 약학적 조성물 및 이의 용도 | |
| WO2022106711A1 (en) | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| AU2026201311A1 (en) | Methods and dosing regimens comprising a CDK2 inhibitor and a CDK4 inhibitor for treating cancer | |
| TW202146007A (zh) | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 | |
| Cofano et al. | The targeted therapies era beyond the surgical point of view: what spine surgeons should know before approaching spinal metastases | |
| Brown | The treatment of relapsed refractory chronic lymphocytic leukemia | |
| WO2022111714A1 (zh) | 用于治疗pik3ca突变癌症的组合疗法 | |
| US20250319186A1 (en) | Treatment of canine cancers | |
| TW202329946A (zh) | 用於治療癌症之方法及包含cdk2抑制劑之給藥方案 | |
| Sukrithan et al. | Kinase inhibitors in thyroid cancers | |
| Gupta et al. | Emerging systemic therapies for the management of penile cancer | |
| Zhao et al. | Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments | |
| CN116159062A (zh) | 药物组合物及其用途 |